See more : Mitsubishi Research Institute, Inc. (3636.T) Income Statement Analysis – Financial Results
Complete financial analysis of Nkarta, Inc. (NKTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nkarta, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Tigers Realm Coal Limited (TIG.AX) Income Statement Analysis – Financial Results
- AnteoTech Limited (ADO.AX) Income Statement Analysis – Financial Results
- M3 Mining Limited (M3M.AX) Income Statement Analysis – Financial Results
- International Data Management Limited (IDM.BO) Income Statement Analysis – Financial Results
- Pacific Green Technologies Inc. (PGTK) Income Statement Analysis – Financial Results
Nkarta, Inc. (NKTX)
About Nkarta, Inc.
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 115.39K | 6.55M |
| Cost of Revenue | 5.87M | 6.57M | 2.12M | 1.05M | 17.22K | 4.25M |
| Gross Profit | -5.87M | -6.57M | -2.12M | -1.05M | 98.17K | 2.30M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 85.08% | 35.08% |
| Research & Development | 96.77M | 90.90M | 63.41M | 36.22M | 17.22M | 4.25M |
| General & Administrative | 34.88M | 28.06M | 23.02M | 15.29M | 5.25M | 2.65M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 34.88M | 28.06M | 23.02M | 15.29M | 5.25M | 2.65M |
| Other Expenses | 0.00 | -470.00K | -16.00K | -40.17M | 1.34M | 0.00 |
| Operating Expenses | 131.65M | 118.96M | 86.43M | 51.51M | 22.46M | 6.91M |
| Cost & Expenses | 131.65M | 118.96M | 86.43M | 51.51M | 22.46M | 6.91M |
| Interest Income | 14.11M | 5.59M | 370.00K | 313.00K | 304.11K | 81.95K |
| Interest Expense | 0.00 | 5.59M | 0.00 | 0.00 | 472.82K | 0.00 |
| Depreciation & Amortization | 5.87M | 6.57M | 2.12M | 1.05M | 553.28K | 183.21K |
| EBITDA | -120.48M | -107.27M | -83.95M | -90.31M | -20.05M | -91.29K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -17,600.68% | -1.39% |
| Operating Income | -131.65M | -118.96M | -86.43M | -51.51M | -22.35M | -356.45K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -19,368.66% | -5.44% |
| Total Other Income/Expenses | 14.15M | 5.12M | 354.00K | -39.85M | 1.27M | 81.95K |
| Income Before Tax | -117.50M | -113.84M | -86.08M | -91.36M | -21.08M | -274.50K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -18,265.66% | -4.19% |
| Income Tax Expense | 0.00 | 5.59M | -2.13M | -40.95M | 1.81M | 81.95K |
| Net Income | -117.50M | -119.43M | -83.95M | -50.41M | -22.88M | -274.50K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -19,832.65% | -4.19% |
| EPS | -2.40 | -2.74 | -2.55 | -1.59 | -2.55 | 0.00 |
| EPS Diluted | -2.40 | -2.74 | -2.55 | -1.59 | -2.55 | 0.00 |
| Weighted Avg Shares Out | 49.01M | 43.63M | 32.86M | 31.80M | 8.98M | 5.03B |
| Weighted Avg Shares Out (Dil) | 49.01M | 43.63M | 32.86M | 31.80M | 8.98M | 5.03B |
The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
Nkarta to Participate in Upcoming Investor Conferences
Huge Insider Buying From Buffett, an NFL Team Owner, a New CEO
Nkarta: NK Cell Therapy Advancement On Two Fronts
Nkarta Announces Pricing of $240 Million Underwritten Offering
Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
3 Overlooked Stocks Ready to Capture the Market by Storm
Nkarta's Strategic Advances In Cell Therapy For Autoimmune Disorders
3 Silent Tech Titans-in-the-Making: Invest Before They Skyrocket
Nkarta to Participate in Upcoming Investor Conferences
Source: https://incomestatements.info
Category: Stock Reports